CGT Global Blog

CGT Global News

Stay ahead in the dynamic world of Accelerating Cell and Gene Therapy with the CGT Global blog and news page. Explore insightful articles, industry updates, product updates, and expert analysis on all things CGT Global. Stay informed, inspired, and connected with CGT Global – your go-to source for cutting-edge insights in the ever-evolving realm of research, clinical projects and healthcare.

New Clinical Grade Non-Transfusable Products

August 21, 2018

[vc_row][vc_column][vc_column_text] New Clinical Grade Non-Transfusable Products StemExpress, a Folsom CA-based leading supplier of human biospecimens, announces the release of Clinical Grade Non-Transfusable products to customers developing studies relating to transplantation, cell therapy, regenerative medicine, investigational new drug (IND) development, and the research and development (R&D) of medical devices in preclinical and clinical phases. The NEW Clinical Grade Non-Transfusable Products support a smooth transition from laboratory prototype to commercial production. The new product line features: Clinical Grade Non-Transfusable Bone Marrow Clinical Grade Non-Transfusable…

Read More

Fresh or Frozen Primary Cells: Helpful tips for choosing the right format for your research.

July 31, 2018

Fresh or Frozen Primary Cells: Which one should I choose? Deciding to purchase fresh or frozen primary cells may not be as simple as you think. There are many factors that may influence your decision, such as cell type, cell functionality, and logistical and timing flexibility. We hope that the following article provides the information you require to make a decision in choosing fresh or frozen primary cells for your specific research.   Fresh Cells At StemExpress, fresh cells are offered as…

Read More

Choosing a Biospecimen Provider

June 25, 2018

Imagine the following scenario. You are close to finalizing the development of a new drug or assay before it enters into clinical trials. However, you encounter a slight setback which requires specific cells you are evaluating to be retested in a key experiment….and you don’t have any vials left! These cells are from a unique donor that fits the criteria you are working with. You contact the hospital which you originally obtained samples from, but the donor is no longer available and…

Read More

CGT Global Exhibiting at BIO International Convention

April 18, 2018

ABOUT THE EVENT The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. TO LEARN MORE, CLICK HERE.

Read More

CGT Global Exhibiting at Clinical Trial Innovation Summit (CTI)

April 18, 2018

ABOUT THE EVENT Cambridge Healthtech Institute’s Clinical Trial Innovation Summit brings together 250 leaders from across pharma, biotech and academia for the perfect blend of high-quality presentations and intimate networking. Through case studies, interactive discussions and an active exhibit hall, the summit delivers the real-world experiences and best practices needed to optimize clinical trial management. Presentations span across the most complex areas of trial management, including patient recruitment, site selection, data integration, leveraging existing data sources, mobile technologies, project management, outsourcing, vendor management, budgeting…

Read More

Folsom’s Innovative Business of the Year 2018

March 29, 2018

We are honored that the Folsom Chamber named StemExpress Innovative Business of the Year 2018! We are so thankful to have our headquarters located in this wonderful community and can truly attest to what a special place it is.   Learn more about the talented individuals and companies recognized this year by reading the Folsom Telegraph article here. FOLSOM’S INNOVATIVE BUSINESS OF THE YEAR 2018 from StemExpress on Vimeo.

Read More

New Stem Cell Collection Center – Folsom, CA

January 30, 2018

Welcome StemExpress’ New Stem Cell Collection Center The demand for human blood products and primary cells has increased, and it shows! After relocating to a larger Collection Center in Folsom, CA in 2016, we quickly outgrew our space – necessitating a more robust facility to accommodate both the needs of our customers and our ever-growing pool of donors. Located in the same parking lot as our laboratory, the new Stem Cell Collection Center spans 4,100 sq. ft., which doubles our footprint of…

Read More

CGT Global Exhibiting at the American Association of Cancer Research

January 18, 2018

StemExpress will be exhibiting at the American Association of Cancer Research Annual Meeting April 14th-18th in Chicago, IL. Stop by and see us.

Read More

CGT Global Exhibiting at Immunology (AAI)

January 17, 2018

Join us in Austin for the leading annual all-immunology event worldwide! At IMMUNOLOGY 2018TM, you’ll hear from global leaders in immunology and talented early-career investigators alike—all discussing breakthroughs

Read More

CGT Global Announces the Release of Diseased Blood Products

December 20, 2017

StemExpress announces the release of our new Diseased Blood Products. We have an extensive and expanding repository of diseased blood, plasma, serum, and peripheral blood mononuclear cells (PBMCs) from donors with autoimmune diseases, infectious diseases, and a variety of cancers. Using our nation-wide Stem Cell Collection Centers, we are able to ensure the delivery of fresh and frozen products to researchers around the world in need of rare blood samples. Our patient samples are ideal for research, as well as new product…

Read More

Blood Biopsies as a Source to Determine Treatment Options for Metastatic Tumors

December 12, 2017

Cancer arises due to the accumulation of alterations in genes that control cell survival, growth, proliferation, and differentiation, which provides a distinct genetic profile of the cancer. This genetic profile is typically assessed using DNA and/or RNA obtained from a biopsy of the primary tumor and aids in providing a therapeutic strategy for dealing with the tumor. However, genomic instability and the ability to evolve to various interactions with microenvironmental cues, including therapeutic drugs, is a hallmark of cancer. Constant and unchecked…

Read More

Exploring the Potential of lncRNAs as Biomarkers for Rheumatoid Arthritis

December 4, 2017

Long noncoding RNAs, also known as lncRNAs, are a large and diverse class of transcribed RNA molecules that are longer than 200 nucleotides and do not code for proteins. Currently, around 35,000 lncRNAs exist in the human genome and are part of the regulatory class of RNAs. Some of these lncRNAs have been fully characterized and take part in gene inhibition or gene activation in mechanisms relating to chromatin modification and structure, direct transcriptional regulation, RNA processing events, protein activity and localization,…

Read More